BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 10, 2008
View Archived Issues
Tumor responses associated with PARP inhibition seen in phase I studies with BSI-201
Read More
Semafore reports positive interim results from phase I study of PI3K inhibitor SF-1126
Read More
Recent patents impart novel compounds for respiratory disorders
Read More
Akorn receives FDA approvable letter for Akten ophthalmic gel 3.5%
Read More
PAC-113 found effective in the treatment of oral candidiasis in phase IIb dose-ranging trial
Read More
New treatment options for neuropsychiatric disorders imparted in recent patents
Read More
BTG completes treatments in Varisolve U.S. phase II safety study
Read More
Update on clinical studies of Boehringer Ingelheim's Polo-like kinase inhibitor BI-2536
Read More
AMANET launches large-scale testing of MSP3-LSP malaria vaccine candidate
Read More
FDA grants pediatric exclusivity to UCB's Keppra until January 2009
Read More
Prucalopride found safe and effective in patients with chronic constipation
Read More
First-in-human results with antisense oligonucleotide LY-2181308 for the treatment of solid tumors
Read More
Oncolytics initiates enrollment in phase II trial of Reolysin with paclitaxel and carboplatin
Read More
Sirtris' novel SIRT1 activator shows efficacy in mouse models of type 2 diabetes
Read More
Akesis completes recruitment and dosing in phase IIa trial of AKP-020 in type 2 diabetes
Read More
BioMarin to initiate phase I/II trial in the first quarter of 2009 of new ERT for MPS IVA
Read More
Anesiva and TFT enter licensing agreement for NF-kappa B clinical program
Read More
Genocea Biosciences and PATH enter collaboration agreement to develop pneumoccocus vaccine
Read More
Gentium presents update on DSMB reviews of phase II/III and phase III trials of defibrotide
Read More
Inspire achieves primary endpoint in phase III denufosol trial in cystic fibrosis
Read More
Vertex reports 52% SVR 12 rate for a 24-week telaprevir-based regimen in HCV
Read More
Targanta Therapeutics submits MAA to EMEA for oritavancin
Read More